Tech Company Inital Public Offerings
Ayala Pharmaceuticals IPO
Operating out of Wilmington, Ayala Pharmaceuticals completed its IPO.
Transaction Overview
Company Name
Announced On
5/7/2020
Transaction Type
IPO
Amount
$55,500,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $13.0 to $14.0 million to advance AL101 through its ongoing Phase 2 ACCURACY trial for the treatment of R/M ACC; approximately $11.0 to $12.0 million to advance AL101 for its planned Phase 2 trial for the treatment of R/M TNBC; approximately $6.0 to $7.0 million to advance AL101 for its planned Phase 2 trial for the treatment of R/R TALL; approximately $7.0 to $8.0 million to advance AL102 for its planned Phase 2 trial for the treatment of desmoid tumors; and the remainder for working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1313 N. Market St. 5100
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Website
Email Address
Overview
Ayala (Nasdaq: AYLA) is a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers. We look to target rare and unique cancers, in which the Notch activation pathway has been dysregulated. Notch is a proven oncogenic driver in defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Roni Mamluk
Chief Financial Officer
Yossi Maimon
Chief Medical Officer
Andrea Vergara-Silva
Vice President
David Caron
VP - Bus. Development
Dana Gelbaum
VP - Human Resources
Irit Klipper-Avni
VP - R & D
Joel Kaye
Browse more venture capital transactions:
Prev: 5/7/2020: Ventus Therapeutics venture capital transaction
Next: 5/7/2020: LetsGetChecked venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs